Entropy Technologies LP Sells 575 Shares of Repligen Co. (NASDAQ:RGEN)

Entropy Technologies LP decreased its holdings in Repligen Co. (NASDAQ:RGEN) by 18.7% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,500 shares of the biotechnology company’s stock after selling 575 shares during the period. Entropy Technologies LP’s holdings in Repligen were worth $372,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds also recently bought and sold shares of RGEN. Andra AP fonden purchased a new position in Repligen in the second quarter valued at about $25,000. International Assets Investment Management LLC bought a new stake in shares of Repligen in the 2nd quarter valued at about $33,000. UMB Bank n.a. grew its position in shares of Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after buying an additional 130 shares during the last quarter. Lazard Asset Management LLC raised its stake in shares of Repligen by 206.1% during the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 136 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in Repligen by 113.4% during the third quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In related news, Director Anthony Hunt sold 22,191 shares of Repligen stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total transaction of $3,225,905.67. Following the transaction, the director now owns 139,840 shares in the company, valued at approximately $20,328,540.80. This trade represents a 13.70 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 1.20% of the stock is currently owned by insiders.

Repligen Stock Down 12.4 %

Shares of RGEN stock opened at $124.73 on Friday. Repligen Co. has a twelve month low of $113.50 and a twelve month high of $211.13. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The stock has a 50 day moving average of $141.54 and a 200 day moving average of $144.77. The stock has a market cap of $6.99 billion, a P/E ratio of -337.10, a P/E/G ratio of 4.36 and a beta of 0.96.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.92%. The business had revenue of $154.87 million during the quarter, compared to analysts’ expectations of $153.34 million. During the same quarter in the previous year, the company earned $0.23 earnings per share. The company’s quarterly revenue was up 9.7% on a year-over-year basis. As a group, sell-side analysts expect that Repligen Co. will post 1.44 EPS for the current year.

Analyst Ratings Changes

RGEN has been the topic of several analyst reports. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the stock an “overweight” rating in a report on Wednesday, July 31st. Royal Bank of Canada restated an “outperform” rating and set a $205.00 target price on shares of Repligen in a research note on Thursday, September 26th. Wells Fargo & Company assumed coverage on Repligen in a research note on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target for the company. Wolfe Research assumed coverage on Repligen in a report on Thursday. They issued a “peer perform” rating for the company. Finally, Benchmark restated a “hold” rating on shares of Repligen in a report on Monday, August 5th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.